Guidelines on the use of high-dose intravenous immunoglobulin in dermatology

Alexander Enk, Anthony Ormerod, European Dermatology Forum Guideline Subcommittee

Research output: Contribution to journalArticlepeer-review

59 Citations (Scopus)


The treatment recommendations presented for the use of IVIg in dermatology highlight the high status of IVIg therapy in numerous defined dermatological autoimmune diseases and in toxic epidermal necrolysis. The high value of IVIg therapy in diseases which are otherwise refractory to treatment is undisputed. A clear case therefore exists for making a treatment recommendation such as described above for the conditions mentioned. Because the mechanism of action of IVIG in vivo is still unclear, however, further efforts should be made to reach standard therapies for the affected patient groups. This would enable even larger case series conducted by different therapists at different sites to be evaluated. Orientation towards the guideline recommendations laid down here should create a basis for this. The implementation of this EU guideline in general practice means that the use of IVIg in dermatology will be optimized throughout Europe.
Original languageEnglish
Pages (from-to)90-98
Number of pages9
JournalEuropean Journal of Dermatology
Issue number1
Publication statusPublished - Jan 2009


  • dermatology
  • humans
  • immunoglobulins, intravenous
  • skin neoplasms
  • IVIg
  • guidelines


Dive into the research topics of 'Guidelines on the use of high-dose intravenous immunoglobulin in dermatology'. Together they form a unique fingerprint.

Cite this